STAT March 19, 2025
Adam Feuerstein

The company is determined to persist with its plans in the face of signs it shouldn’t

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Pharma Dodges The Tariff Bullet — But For How Long?
PBM Private Labeling Boosts Biosimilars, Raises Concerns
Biotech ‘megarounds’ hold steady as startups, VCs wait on IPOs
How BioPharma Can Improve Consumers’ Experience and Health
The Go-To Law Firms For Healthcare and Life Sciences

Share This Article